Drug intelligence / Profile preview

MTX101

Development stage: Phase 2
Lead developer: Manistee Therapeutics
Administration: Sublingual

Overview

MTX101 is an investigational drug developed by Manistee Therapeutics for the acute treatment of migraine headaches in adults. It is administered as a 2 mg sublingual tablet. The drug is currently being evaluated in a Phase 2a clinical study to assess its safety and efficacy in reducing headache pain and the need for rescue medication during acute migraine attacks. The specific mechanism of action for MTX101 is not detailed in the provided context.

Targets

KIR2DL3CD8A (CD8 alpha/beta Coreceptor)KIR2DL2 (Killer cell immunoglobulin-like receptor 2DL2)KIR2DL1

Beyond the preview

Go deeper on MTX101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX101.

Explore the full profile